Suven gets product patents for Neurodegenerative disorders

Suven Life Sciences was granted two product patents by Australia and Singapore corresponding to a new chemical entity (NCE) for the treatment of neurodegenerative disorders.

“We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life CEO Venkat Jasti said.

The granted claims of the patents are being developed as therapeutic agents useful in the treatment of cognitive impairment neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s and schizophrenia, the BSE filing stated.


Please enter your comment!
Please enter your name here